Key points are not available for this paper at this time.
W e have come a long way since the identification of the first human tumor antigen recognized by autologous CTL. This report provides a brief appraisal of these antigens and their potential for cancer immunotherapy. Our comments will be restricted to nonviral antigens.
Boon et al. (Fri,) studied this question.